tradingkey.logo
tradingkey.logo
Search

Harmony falls as genetic disorder drug fails late-stage trial

ReutersSep 24, 2025 1:55 PM
facebooktwitterlinkedin
View all comments0

Shares of drug developer Harmony Biosciences HRMY.O fall 7.6% to $29.7

Company says its experimental drug, ZYN002, did not meet the main goal of a late-stage trial testing it in patients with Fragile X syndrome

Fragile X syndrome is a genetic disorder and one of the most common causes of inherited intellectual disability

HRMY says the drug did not meet the main goal of improvement in social avoidance primarily due to a higher-than-expected placebo response rate

Including session's move, stock down 12.7% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI